Plus Therapeutics (PSTV)

Company Profile

Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.

Company profile

Ticker

PSTV

Exchange

NASDAQ

Website

www.plustherapeutics.com

CEO

Marc Hedrick

Incorporated

Delaware

Location

Texas

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...

Former names

CYTORI THERAPEUTICS, INC., MACROPORE INC

SEC CIK

0001095981

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

IRS number

330827593

PSTV stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

28 Nov 22

8-K

Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

20 Oct 22

Plus Therapeutics Executes $17.6 Million Award Contract with Cancer

22 Sep 22

8-K

Entry into a Material Definitive Agreement

9 Sep 22

424B5

Prospectus supplement for primary offering

9 Sep 22

EFFECT

Notice of effectiveness

18 Aug 22

424B3

Prospectus supplement

Transcripts

View all

PSTV

Earnings call transcript

2022 Q3

21 Oct 22

PSTV

Earnings call transcript

2022 Q2

21 Jul 22

PSTV

Earnings call transcript

2022 Q1

22 Apr 22

PSTV

Earnings call transcript

2021 Q4

25 Feb 22

PSTV

Earnings call transcript

2021 Q3

22 Oct 21

PSTV

Earnings call transcript

2021 Q2

23 Jul 21

PSTV

Earnings call transcript

2021 Q1

23 Apr 21

PSTV

Earnings call transcript

2020 Q4

23 Feb 21

PSTV

Earnings call transcript

2020 Q3

22 Oct 20

PSTV

Earnings call transcript

2020 Q2

10 Aug 20

Latest ownership filings

View all

Andrew John Hugh MacIntyre Sims

Andrew John Hugh MacIntyre Sims

3 Mar 22

SC 13G/A

INTRACOASTAL CAPITAL, LLC

11 Feb 22

Financial summary

Financial statements Chart PSTV financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	20.27 mm	20.27 mm	20.27 mm	20.27 mm	20.27 mm	20.27 mm
Cash burn (monthly)	(no burn)	84.50 k	1.70 mm	1.51 mm	1.41 mm	1.11 mm
Cash used (since last report)	n/a	355.26 k	7.14 mm	6.33 mm	5.92 mm	4.68 mm
Cash remaining	n/a	19.91 mm	13.13 mm	13.93 mm	14.35 mm	15.58 mm
Runway (months of cash)	n/a	235.6	7.7	9.2	10.2	14.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

PSTV institutional ownership history Ownership history

12.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	27	26	+3.8%
Opened positions	3	3	–
Closed positions	2	1	+100.0%
Increased positions	4	7	-42.9%
Reduced positions	7	4	+75.0%

13F shares	Current	Prev Q	Change
Total value	2.34 mm	2.71 mm	-13.6%
Total shares	4.03 mm	4.10 mm	-1.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Parkman Healthcare Partners	1.33 mm	$590.00 k	-13.6%
Vanguard	1.09 mm	$486.00 k	+27.7%
Otter Creek Advisors	330.17 k	$147.00 k	0.0%
Intracoastal Capital	300.00 k	$315.00 k	0.0%
Geode Capital Management	258.44 k	$115.00 k	0.0%
NanoTx	230.77 k	$466.00 k	0.0%
BLK Blackrock	104.43 k	$46.00 k	0.0%
Renaissance Technologies	70.90 k	$32.00 k	-29.9%
Two Sigma Securities	64.11 k	$29.00 k	NEW
Susquehanna International	46.23 k	$21.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Vanguard	1.09 mm	+237.30 k	+27.7%
Parkman Healthcare Partners	1.33 mm	-208.05 k	-13.6%
MS Morgan Stanley	6.00	-118.42 k	-100.0%
Two Sigma Securities	64.11 k	+64.11 k	NEW
Susquehanna International	46.23 k	+46.23 k	NEW
STT State Street	0.00	-34.41 k	EXIT
Renaissance Technologies	70.90 k	-30.19 k	-29.9%
Citadel Advisors	16.77 k	+16.77 k	NEW
Warberg Asset Management	10.00 k	-15.10 k	-60.2%
Tower Research Capital	9.70 k	-10.45 k	-51.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PSTV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Dec 22	Robert P Lenk	Common Stock	Sell	Dispose S	No	No	0.3147	1,500	472.05	8,500
15 Jun 22	Hedrick Marc H	Common Stock	Buy	Acquire P	No	No	0.648	5,000	3.24 k	33,580
2 Jun 22	Howard Clowes	Common Stock	Buy	Acquire P	No	No	0.5726	15,000	8.59 k	18,000
17 May 22	Petersen Greg	Common Stock	Buy	Acquire P	No	No	0.55	30,000	16.50 k	62,500
26 Apr 22	Hedrick Marc H	Common Stock	Buy	Acquire P	No	No	0.6841	2,500	1.71 k	28,580